JPWO2020031936A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020031936A5 JPWO2020031936A5 JP2020535747A JP2020535747A JPWO2020031936A5 JP WO2020031936 A5 JPWO2020031936 A5 JP WO2020031936A5 JP 2020535747 A JP2020535747 A JP 2020535747A JP 2020535747 A JP2020535747 A JP 2020535747A JP WO2020031936 A5 JPWO2020031936 A5 JP WO2020031936A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- amino acid
- drug conjugate
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024043043A JP2024075668A (ja) | 2018-08-06 | 2024-03-19 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
| JP2024158824A JP2024178243A (ja) | 2018-08-06 | 2024-09-13 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018147582 | 2018-08-06 | ||
| JP2018147582 | 2018-08-06 | ||
| PCT/JP2019/030635 WO2020031936A1 (ja) | 2018-08-06 | 2019-08-05 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024043043A Division JP2024075668A (ja) | 2018-08-06 | 2024-03-19 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020031936A1 JPWO2020031936A1 (ja) | 2021-08-10 |
| JPWO2020031936A5 true JPWO2020031936A5 (enExample) | 2022-08-15 |
| JP7458981B2 JP7458981B2 (ja) | 2024-04-01 |
Family
ID=69414755
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020535747A Active JP7458981B2 (ja) | 2018-08-06 | 2019-08-05 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
| JP2024043043A Pending JP2024075668A (ja) | 2018-08-06 | 2024-03-19 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
| JP2024158824A Pending JP2024178243A (ja) | 2018-08-06 | 2024-09-13 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024043043A Pending JP2024075668A (ja) | 2018-08-06 | 2024-03-19 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
| JP2024158824A Pending JP2024178243A (ja) | 2018-08-06 | 2024-09-13 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3834843A4 (enExample) |
| JP (3) | JP7458981B2 (enExample) |
| KR (1) | KR20210042120A (enExample) |
| CN (1) | CN112512587A (enExample) |
| AU (2) | AU2019320336B2 (enExample) |
| BR (1) | BR112021001750A2 (enExample) |
| CA (1) | CA3108754A1 (enExample) |
| EA (1) | EA202190471A1 (enExample) |
| TW (1) | TW202019487A (enExample) |
| WO (1) | WO2020031936A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019039483A1 (ja) * | 2017-08-23 | 2019-02-28 | 第一三共株式会社 | 抗体－薬物コンジュゲートの製剤及びその凍結乾燥方法 |
| BR112021023901A2 (pt) * | 2019-05-29 | 2022-01-18 | Daiichi Sankyo Co Ltd | Conjugado anticorpo-fármaco anti-trop2, composição farmacêutica, método para tratar ou prevenir câncer, e, uso de um conjugado anticorpo-fármaco anti-trop2 na fabricação de um fármaco para o tratamento ou prevenção do câncer |
| CA3173263A1 (en) * | 2020-03-30 | 2021-10-07 | Yasuhiro Matsumura | Antibody drug conjugate |
| WO2022074617A1 (en) * | 2020-10-09 | 2022-04-14 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and parp1 selective inhibitor |
| WO2022099762A1 (zh) * | 2020-11-12 | 2022-05-19 | 博瑞生物医药（苏州）股份有限公司 | 一种抗体偶联物中间体及其制备方法 |
| WO2022126569A1 (zh) * | 2020-12-18 | 2022-06-23 | 上海复旦张江生物医药股份有限公司 | 一种靶向b7-h3的抗体药物偶联物、其制备方法及应用 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| EP4393514A1 (en) * | 2021-08-24 | 2024-07-03 | Kunshan Xinyunda Biotech Co., Ltd. | Antibody-drug conjugate conjugated via breakable linker |
| CN118317795A (zh) * | 2021-09-15 | 2024-07-09 | 第一三共株式会社 | 用在治疗化疗耐药性癌症的方法中的抗体-药物偶联物 |
| CN119255825A (zh) * | 2022-05-24 | 2025-01-03 | 第一三共株式会社 | 抗-cdh6抗体-药物缀合物的剂量方案 |
| CN118955615A (zh) * | 2022-07-05 | 2024-11-15 | 上海药明合联生物技术有限公司 | 偶联连接子 |
| AU2024236246A1 (en) * | 2023-03-14 | 2025-10-30 | Daiichi Sankyo Company, Limited | Combination of anti-CDH6 antibody-drug conjugate and VEGF inhibitor |
| AU2024248799A1 (en) * | 2023-03-31 | 2025-10-23 | Daiichi Sankyo Company, Limited | Combination of anti-CDH6 antibody-drug conjugate and HIF-2alpha inhibitor |
| CN119546347A (zh) * | 2023-06-29 | 2025-02-28 | 石药集团巨石生物制药有限公司 | 抗体-药物偶联物及其用途 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| GEP20104998B (en) | 1999-06-25 | 2010-06-10 | Genentech Inc | Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer |
| EA013563B1 (ru) | 2000-10-06 | 2010-06-30 | Киова Хакко Кирин Ко., Лтд. | Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| US20060045877A1 (en) | 2004-08-30 | 2006-03-02 | Goldmakher Viktor S | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
| ATE476994T1 (de) | 2004-11-30 | 2010-08-15 | Curagen Corp | Antikörper gegen gpnmb und ihre verwendungen |
| US20070160617A1 (en) | 2005-06-20 | 2007-07-12 | Psma Development Company, Llc | PSMA antibody-drug conjugates |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| CA2647632C (en) | 2006-03-27 | 2017-06-27 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| HRP20131113T1 (hr) | 2007-02-16 | 2014-01-17 | Merrimack Pharmaceuticals, Inc. | Protutijela protiv erbb3 i njihova uporaba |
| CN101903403B (zh) | 2007-10-19 | 2016-03-16 | 西雅图基因公司 | Cd19结合剂及其应用 |
| UY32560A (es) | 2009-04-29 | 2010-11-30 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| BR112014019825B1 (pt) | 2012-02-10 | 2021-08-24 | University Of Maryland, Baltimore | Glicoengenharia quimioenzimática de anticorpos e fragmentos fc dos mesmos |
| KR102498405B1 (ko) | 2012-10-11 | 2023-02-09 | 다이이찌 산쿄 가부시키가이샤 | 글리신아미드 화합물의 제조 방법 |
| WO2014061277A1 (ja) | 2012-10-19 | 2014-04-24 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート |
| CN103239455A (zh) * | 2012-12-24 | 2013-08-14 | 苏州大学 | 有协同治疗效果和高载药量的多组分纳米药物的制备方法 |
| PT3088419T (pt) | 2013-12-25 | 2019-01-11 | Daiichi Sankyo Co Ltd | Conjugado de anticorpo anti-trop2-fármaco |
| CA2928794C (en) | 2014-01-31 | 2019-08-13 | Daiichi Sankyo Company, Limited | Anti-her2 antibody-drug conjugate |
| JP2017114763A (ja) | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗ｃｄ９８抗体−薬物コンジュゲート |
| RU2711640C2 (ru) | 2014-04-10 | 2020-01-17 | Дайити Санкио Компани, Лимитед | Конъюгат анти-her3 антитело-лекарственное средство |
| WO2015155976A1 (ja) | 2014-04-10 | 2015-10-15 | 第一三共株式会社 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
| KR20170040249A (ko) * | 2014-08-12 | 2017-04-12 | 노파르티스 아게 | 항-cdh6 항체 약물 접합체 |
| DK3262071T3 (da) | 2014-09-23 | 2020-06-15 | Hoffmann La Roche | Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater |
| PT3313443T (pt) * | 2015-06-25 | 2023-08-30 | Immunomedics Inc | Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro |
| CN107922477B (zh) * | 2015-06-29 | 2022-11-01 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| CN116440279A (zh) | 2015-09-17 | 2023-07-18 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
| KR20180123214A (ko) * | 2015-12-09 | 2018-11-15 | 난트 홀딩스 아이피, 엘엘씨 | Her2 양성 전이성 유방암의 치료를 위한 조성물 및 방법 |
| KR102456433B1 (ko) | 2016-03-02 | 2022-10-19 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 에리불린-기반 항체-약물 콘주게이트 및 사용 방법 |
| US11273155B2 (en) * | 2016-12-12 | 2022-03-15 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
| KR102537651B1 (ko) | 2017-01-17 | 2023-05-26 | 다이이찌 산쿄 가부시키가이샤 | 항 gpr20 항체 및 항 gpr20 항체-약물 콘쥬게이트 |
| TW202530219A (zh) | 2017-05-15 | 2025-08-01 | 日商第一三共股份有限公司 | 抗體－藥物結合物之製造方法 |
| AU2018327171B2 (en) | 2017-08-31 | 2023-03-09 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
-
2019
- 2019-08-05 CA CA3108754A patent/CA3108754A1/en active Pending
- 2019-08-05 BR BR112021001750-0A patent/BR112021001750A2/pt unknown
- 2019-08-05 CN CN201980052170.5A patent/CN112512587A/zh active Pending
- 2019-08-05 AU AU2019320336A patent/AU2019320336B2/en active Active
- 2019-08-05 WO PCT/JP2019/030635 patent/WO2020031936A1/ja not_active Ceased
- 2019-08-05 EP EP19847036.1A patent/EP3834843A4/en active Pending
- 2019-08-05 TW TW108127750A patent/TW202019487A/zh unknown
- 2019-08-05 KR KR1020217006189A patent/KR20210042120A/ko not_active Ceased
- 2019-08-05 EA EA202190471A patent/EA202190471A1/ru unknown
- 2019-08-05 JP JP2020535747A patent/JP7458981B2/ja active Active
-
2024
- 2024-03-19 JP JP2024043043A patent/JP2024075668A/ja active Pending
- 2024-09-13 JP JP2024158824A patent/JP2024178243A/ja active Pending
-
2025
- 2025-09-04 AU AU2025226765A patent/AU2025226765A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020031936A5 (enExample) | ||
| JPWO2020122034A5 (enExample) | ||
| JP2025041725A5 (enExample) | ||
| AU2019411289B2 (en) | Improved cell-targeting binding molecule | |
| JP7458981B2 (ja) | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ | |
| JP6328649B2 (ja) | 薬物−タンパク質コンジュゲート | |
| HRP20231609T1 (hr) | Konjugati lijeka koji sadrže antitijela protiv klaudina 18.2 | |
| JP6473138B2 (ja) | 癌、特に前立腺癌を標的とする合成抗体模倣化合物（ＳｙＡＭ） | |
| JP2008546792A5 (enExample) | ||
| JP2013100314A5 (enExample) | ||
| JP2020524675A5 (enExample) | ||
| JP2017528418A5 (enExample) | ||
| TWI838358B (zh) | 疏水性奧瑞他汀(auristatin)f化合物及其結合物 | |
| CA2967077A1 (en) | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin | |
| JP2015500287A (ja) | 抗体−薬物のコンジュゲート、ならびに関連する化合物、組成物および方法 | |
| RU2016150377A (ru) | Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc | |
| JP2018509394A5 (enExample) | ||
| JP2016511637A5 (enExample) | ||
| JP2012522512A5 (enExample) | ||
| JP2018537975A5 (enExample) | ||
| US20170281787A1 (en) | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin | |
| JP2020515578A5 (enExample) | ||
| JP2014508767A (ja) | 改善されたリンケージを有するアマトキシン複合体 | |
| JPWO2020027100A5 (enExample) | ||
| JPWO2022102634A5 (enExample) |